EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Significance of Siglec‐15 expression in colorectal cancer: association with advanced disease stage and fewer tumor‐infiltrating lymphocytes

Zhao Lu, Pu Cheng, Fei Huang, Jiyun Li, Bingzhi Wang, Shuangmei Zou, Zhaoxu Zheng, Chunwei Peng

The Journal of Pathology: Clinical Research · 2023-03 · 9 (2) · 121-128

DOI: 10.1002/cjp2.303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 24.11.2022. Verfasst von Zhao Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, PR China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Lymphocytes, Tumor-Infiltrating, Sialic Acid Binding Immunoglobulin-like Lectins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Siglec‐15, a novel immune suppressor, is upregulated in many human cancers. The aim of this study was to explore the expression of Siglec‐15 in colorectal cancer (CRC), and investigate whether Siglec‐15 could be a potential target for cancer immunotherapy in patients with CRC. We performed immunohistochemical analyses of Siglec‐15 on a cohort of 805 patients with CRC and made comparisons between clinicopathological characteristics, PD‐L1 expression, CD3, CD8, CD45RO tumor‐infiltrating lymphocytes (TILs), and prognosis. We found that Siglec‐15 expression was commonly detected in tumor cells (48.3%) and tumor‐associated stromal cells (33.4%), and was more frequently observed than PD‐L1 expression in tumor cells. In contrast, Siglec‐15 expression was weakly and scarcely found in normal mucosa (13%). Siglec‐15 overexpression in tumor cells was associated with advanced TNM stage ( p = 0.020). Co‐expression of Siglec‐15 and PD‐L1 in tumor cells was found in 14.4% of patients, and Siglec‐15 expression was detected in almost half of PD‐L1 negative cases. Elevated Siglec‐15 expression in tumor and stromal cells was associated with sparser CD45RO and CD8 TILs ( p = 0.035 and p = 0.004, respectively). The expression of Siglec‐15 did not have prognostic significance. In summary, compared to PD‐L1, Siglec‐15 protein expression is more prevalent in CRC and is associated with advanced disease stage and fewer TILs. These findings support Siglec‐15 as a potential cancer immunotherapy target, in addition to PD‐1/PD‐L1 inhibitors, in patients with CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLymphocytes, Tumor-InfiltratingSialic Acid Binding Immunoglobulin-like LectinsHumansB7-H1 AntigenPrognosisImmunoglobulinsMembrane Proteins

Stichwörter der Autor:innen

PD-L1Siglec-15colorectal cancertumor-infiltrating lymphocytes

Substanzen

B7-H1 AntigenSialic Acid Binding Immunoglobulin-like LectinsSIGLEC15 protein, humanImmunoglobulinsMembrane Proteins

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, PR China.
  • Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.

Zitieren

APA

Lu, Z., Cheng, P., Huang, F., Li, J., Wang, B., Zou, S., Zheng, Z., & Peng, C. (2023). Significance of Siglec‐15 expression in colorectal cancer: association with advanced disease stage and fewer tumor‐infiltrating lymphocytes. The Journal of Pathology: Clinical Research, 9(2), 121-128. https://doi.org/10.1002/cjp2.303

Vancouver

Lu Z, Cheng P, Huang F, Li J, Wang B, Zou S, et al. Significance of Siglec‐15 expression in colorectal cancer: association with advanced disease stage and fewer tumor‐infiltrating lymphocytes. The Journal of Pathology: Clinical Research. 2023;9(2):121-128. doi:10.1002/cjp2.303

BibTeX
@article{Lu2023,
  author = {Lu, Zhao and Cheng, Pu and Huang, Fei and Li, Jiyun and Wang, Bingzhi and Zou, Shuangmei and Zheng, Zhaoxu and Peng, Chunwei},
  title = {Significance of Siglec‐15 expression in colorectal cancer: association with advanced disease stage and fewer tumor‐infiltrating lymphocytes},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2023},
  volume = {9},
  number = {2},
  pages = {121--128},
  doi = {10.1002/cjp2.303}
}
Kostenlos starten →